521 related articles for article (PubMed ID: 31881294)
1. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data.
Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG
J Am Acad Dermatol; 2020 May; 82(5):1150-1157. PubMed ID: 31881294
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa.
Tzellos T; van Straalen KR; Kyrgidis A; Alavi A; Goldfarb N; Gulliver W; Jemec GBE; Lowes MA; Marzano AV; Prens EP; Sayed CJ; van der Zee HH; Zouboulis CC
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):395-401. PubMed ID: 36184889
[TBL] [Abstract][Full Text] [Related]
3. Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab.
Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG
Clin Exp Dermatol; 2021 Mar; 46(2):306-313. PubMed ID: 32931599
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
Glatt S; Jemec GBE; Forman S; Sayed C; Schmieder G; Weisman J; Rolleri R; Seegobin S; Baeten D; Ionescu L; Zouboulis CC; Shaw S
JAMA Dermatol; 2021 Nov; 157(11):1279-1288. PubMed ID: 34406364
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB
Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379
[TBL] [Abstract][Full Text] [Related]
7. Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab.
Caposiena Caro RD; Cannizzaro MV; Tartaglia C; Bianchi L
Clin Exp Dermatol; 2020 Jun; 45(4):438-444. PubMed ID: 31630436
[TBL] [Abstract][Full Text] [Related]
8. Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa.
Aarts P; van Huijstee JC; van der Zee HH; van Straalen KR; Prens EP
J Eur Acad Dermatol Venereol; 2024 May; 38(5):904-909. PubMed ID: 38112226
[TBL] [Abstract][Full Text] [Related]
9. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.
Kimball AB; Sobell JM; Zouboulis CC; Gu Y; Williams DA; Sundaram M; Teixeira HD; Jemec GB
J Eur Acad Dermatol Venereol; 2016 Jun; 30(6):989-94. PubMed ID: 26201313
[TBL] [Abstract][Full Text] [Related]
10. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.
Zouboulis CC; Okun MM; Prens EP; Gniadecki R; Foley PA; Lynde C; Weisman J; Gu Y; Williams DA; Jemec GBE
J Am Acad Dermatol; 2019 Jan; 80(1):60-69.e2. PubMed ID: 29860040
[TBL] [Abstract][Full Text] [Related]
11. Clinical selection criteria in new clinical trials of hidradenitis suppurativa: External validity and implications on the daily clinical practice.
Montero-Vilchez T; Salvador-Rodriguez L; Sanchez-Diaz M; Cuenca-Barrales C; Martinez-Lopez A; Arias-Santiago S; Molina-Leyva A
Dermatol Ther; 2020 Nov; 33(6):e14254. PubMed ID: 32860480
[TBL] [Abstract][Full Text] [Related]
12. Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II.
Kimball AB; Tzellos T; Calimlim BM; Teixeira HD; Geng Z; Okun MM
Acta Derm Venereol; 2018 Nov; 98(10):932-937. PubMed ID: 30085324
[TBL] [Abstract][Full Text] [Related]
13. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
Kimball AB; Okun MM; Williams DA; Gottlieb AB; Papp KA; Zouboulis CC; Armstrong AW; Kerdel F; Gold MH; Forman SB; Korman NJ; Giamarellos-Bourboulis EJ; Crowley JJ; Lynde C; Reguiai Z; Prens EP; Alwawi E; Mostafa NM; Pinsky B; Sundaram M; Gu Y; Carlson DM; Jemec GB
N Engl J Med; 2016 Aug; 375(5):422-34. PubMed ID: 27518661
[TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study.
Gulliver W; Alavi A; Wiseman MC; Gooderham MJ; Rao J; Alam MS; Papp KA; Desjardins O; Jean C
J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):2431-2439. PubMed ID: 34378812
[TBL] [Abstract][Full Text] [Related]
15. External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort.
van Straalen KR; Tzellos T; Alavi A; Benhadou F; Cuenca-Barrales C; Daxhelet M; Daoud M; Efthymiou O; Giamarellos-Bourboulis EJ; Guillem P; Gulliver W; Jemec GBE; Katoulis A; Koenig A; Lazaridou E; Lowes MA; Marzano AV; Matusiak L; Molina-Leyva A; Moltrasio C; Pinter A; Potenza C; Prens EP; Romaní J; Saunte DM; Sayed C; Skroza N; Stergianou D; Szepietowski JC; Trigoni A; Vilarrasa E; Kyrgidis A; Zouboulis CC; van der Zee HH
Dermatology; 2023; 239(3):362-367. PubMed ID: 36630943
[TBL] [Abstract][Full Text] [Related]
16. Certolizumab pegol in the treatment of severe hidradenitis suppurativa after adalimumab failure: A real-life experience.
Esme P; Akoglu G; Dalkıran CD; Caliskan E
Dermatol Ther; 2022 Nov; 35(11):e15782. PubMed ID: 35996992
[TBL] [Abstract][Full Text] [Related]
17. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
[TBL] [Abstract][Full Text] [Related]
18. Infection-free Clinical Response Among Patients With Hidradenitis Suppurativa Who Were Treated With Adalimumab: Results from Two Phase 3 Studies.
Giamarellos-Bourboulis EJ; Sobell J; Ryan C; Wolkenstein PJ; Geng Z; Mulder GD
Wounds; 2017 Nov; 29(11):E98-E102. PubMed ID: 29166256
[TBL] [Abstract][Full Text] [Related]
19. Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: Clinical and ultrasound observations.
Caposiena Caro RD; Cannizzaro MV; Botti E; Di Raimondo C; Di Matteo E; Gaziano R; Bianchi L
J Am Acad Dermatol; 2019 May; 80(5):1314-1321. PubMed ID: 30502416
[TBL] [Abstract][Full Text] [Related]
20. Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.
Zouboulis CC; Passeron T; Pariser D; Wozniak MB; Li X; Uhlmann L; Lobach I; Martinez AL; Ravichandran S; Alarcon I; Offidani A; Alam MS; Mendes-Bastos P
Br J Dermatol; 2024 May; 190(6):836-845. PubMed ID: 38470171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]